Borenstein Hali
Known title: CEO and PresidentCIK: 0001795710
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Carter's Stock Faces Slip and Lowered Price Target. Recent coverage notes that Carter's shares fell sharply, prompting a price target reduction to $30 by Wells Fargo. Analysts highlighted warning signs in the Russell 2000 and described the stock as potentially undervalued after a 60% decline. The company’s dividend yield of 4.4% and low P/E of 5.9 are cited as attractive income features, while the stock trades near its $37.59 support level.
Transaction History
| REF | ▼ Sell | Other | 170,876 | $2.4M | 7/31/2026 | View on chart |
| REF | ▲ Buy | Grant | 300,000 | $0 | 7/29/2026 | View on chart |
| REF | ▲ Buy | Grant | 666,666 | $0 | 7/29/2026 | View on chart |
| REF | ▲ Buy | Grant | 166,666 | $0 | 7/29/2026 | View on chart |
| CRI | ▲ Buy | Grant | 13 | $0 | 3/27/2026 | View on chart |
| CRI | ▲ Buy | Grant | 15 | $0 | 12/5/2025 | View on chart |
| CRI | ▲ Buy | Grant | 17 | $0 | 9/12/2025 | View on chart |
| CRI | ▲ Buy | Grant | 15 | $0 | 6/20/2025 | View on chart |
| CRI | ▲ Buy | Grant | 4,409 | $0 | 5/15/2025 | View on chart |
| CRI | ▲ Buy | Grant | 32 | $0 | 3/28/2025 | View on chart |
| CRI | ▲ Buy | Grant | 25 | $0 | 12/6/2024 | View on chart |
| CRI | ▲ Buy | Grant | 20 | $0 | 9/13/2024 | View on chart |
| CRI | ▲ Buy | Grant | 21 | $0 | 6/7/2024 | View on chart |
| CRI | ▲ Buy | Grant | 2,293 | $0 | 5/16/2024 | View on chart |
| CRI | ▲ Buy | Grant | 16 | $0 | 3/29/2024 | View on chart |
| CRI | ▲ Buy | Grant | 19 | $0 | 12/8/2023 | View on chart |
| CRI | ▲ Buy | Grant | 17 | $0 | 9/15/2023 | View on chart |
| CRI | ▲ Buy | Grant | 19 | $0 | 6/9/2023 | View on chart |
| CRI | ▲ Buy | Grant | 2,385 | $0 | 5/18/2023 | View on chart |
| CRI | ▲ Buy | Grant | 17 | $0 | 3/17/2023 | View on chart |
| CRI | ▲ Buy | Grant | 16 | $0 | 12/9/2022 | View on chart |
| CRI | ▲ Buy | Grant | 16 | $0 | 9/16/2022 | View on chart |
| CRI | ▲ Buy | Grant | 15 | $0 | 6/10/2022 | View on chart |
| CRI | ▲ Buy | Grant | 1,975 | $0 | 5/19/2022 | View on chart |
| CRI | ▲ Buy | Grant | 13 | $0 | 3/18/2022 | View on chart |
| CRI | ▲ Buy | Grant | 9 | $0 | 12/10/2021 | View on chart |
| CRI | ▲ Buy | Grant | 6 | $0 | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Reformation IPO faces limited near-term catalysts
Recent analysis suggests Reformation's recent IPO may lack immediate drivers for significant price movement. This context is relevant as the stock trades within a $12.83 to $17.26 range over the past year. Analysts currently set an average target price of $19.25, indicating potential upside from current levels despite the noted lack of short-term news.
Reformation IPO faces limited near-term catalysts. Recent analysis suggests Reformation's recent IPO may lack immediate drivers for significant price movement. This context is relevant as the stock trades within a $12.83 to $17.26 range over the past year. Analysts currently set an average target price of $19.25, indicating potential upside from current levels despite the noted lack of short-term news.